Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original Research

Understanding and addressing vaccine hesitancy in the context of COVID-19: development of a digital intervention

H. Knight a, R. Jia a, K. Aying b, K. Bradbury b, c, K. Baker b, T. Chalder d, J.R. Morling a, e, L. Durrant a, T. Averya, J.K. Ball f, C. Barker b, R. Bennett g, T. McKeever a, K. Vedhara a, *

a University of Nottingham, School of Medicine, Nottingham, UK
b National Institute for Health Research (NIHR) ARC Wessex, UK
c University of Southampton, Department of Psychology, Southampton, UK
d Kings College London, Department of Psychological Medicine, London, UK
e National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK
f University of Nottingham, School of Life Sciences, Nottingham, UK
g Rehab Studio LTD, London, UK

A R T I C L E   I N F O

Article history:
Received 30 July 2021
Received in revised form 29 September 2021
Accepted 10 October 2021
Available online 18 October 2021

Keywords:
COVID-19
Vaccine hesitancy
Intervention
Motivational interviewing

A B S T R A C T

Objectives: Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) was identified in late 2019, spreading to over 200 countries and resulting in almost two million deaths worldwide. The emergence of safe and effective vaccines provides a route out of the pandemic, with vaccination uptake of 75–90% needed to achieve population protection. Vaccine hesitancy is problematic for vaccine rollout; global reports suggest only 73% of the population may agree to being vaccinated. As a result, there is an urgent need to develop equitable and accessible interventions to address vaccine hesitancy at the population level.

Study design & Method: We report the development of a scalable digital intervention seeking to address COVID-19 vaccine hesitancy and enhance uptake of COVID-19 vaccines in the United Kingdom. Guided by motivational interviewing (MI) principles, the intervention includes a series of therapeutic dialogues addressing 10 key concerns of vaccine-hesitant individuals. Development of the intervention occurred linearly across four stages. During stage 1, we identified common reasons for COVID-19 vaccine hesitancy through analysis of existing survey data, a rapid systematic literature review, and public engagement workshops. Stage 2 comprised qualitative interviews with medical, immunological, and public health experts. Rapid content and thematic analysis of the data provided evidence-based responses to common vaccine concerns. Stage 3 involved the development of therapeutic dialogues through workshops with psychological and digital behaviour change experts. Rapid content and thematic analysis of the data provided evidence-based responses to common vaccine concerns. Stage 4 involved digitisation of the dialogues and pilot testing with members of the public.

Discussion: The digital intervention provides an evidence-based approach to addressing vaccine hesitancy through MI principles. The dialogues are user-selected, allowing exploration of relevant issues associated with hesitancy in a non-judgmental context. The text-based content and digital format allow for rapid modification to changing information and scalability for wider dissemination.

© 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

Introduction

Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) was identified in late 2019. At the time of writing, the latest estimates suggest that it has spread to over 200 countries and has resulted in the deaths of almost two million people.1 The resulting global pandemic has seriously affected the social and economic fabric of societies everywhere and the physical and mental health crisis continues.2 Safe and effective vaccines provide a route out of this crisis, but the development of these vaccines, while necessary, is not sufficient. For vaccines to achieve their full potential, the public also needs to be willing to be vaccinated. Recent data suggest this cannot be assumed. A recent survey of United Kingdom (UK) households indicated that approximately 82% of the population would agree to be vaccinated.3 This estimate should be viewed

https://doi.org/10.1016/j.puhe.2021.10.006
0033-3506/© 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.
against a backdrop of declines in vaccine intent overall and the fact that it masks large variations in intent between demographic groups. Vaccine hesitancy, defined as a ‘delay in acceptance or refusal of vaccines despite availability of vaccine services’\(^{14}\) may significantly impact the uptake of COVID-19 vaccines, particularly amongst ethnic minorities, women, and those with less education.\(^{3,5,6}\) If, as has been suggested, 75–90% of a population will need to be vaccinated for community protection to be achieved,\(^{7}\) then there is an urgent need to develop equitable and accessible interventions to address vaccine hesitancy at the population level within the United Kingdom.

Attempts to improve vaccine uptake are not new and have focussed traditionally on approaches such as information/education, incentives\(^{8–10}\) and reminders. However, results from successive reviews suggest that the evidence-based support of any one approach remains limited.\(^{11–13}\) Furthermore, much of the work has been conducted in the context of adults making decisions for their dependents, rather than adults making decisions for themselves. The generalisability of these findings to COVID-19 vaccines in adults is, therefore, unclear. Nonetheless, much can be gleaned from the existing evidence: information, while necessary, is unlikely to improve vaccine uptake on its own, and interventions need to engage with individuals’ reasons for hesitancy, i.e. their hesitancy cognitions.\(^{12}\)

We report here a roadmap for the development of a scalable digital intervention, which seeks to address the concerns of individuals who are vaccine-hesitant, with a view to enhancing the uptake of COVID-19 vaccines. We report the process we followed in developing a digital vaccine hesitancy intervention suitable for adults considering a COVID-19 vaccination. While primary data were collected within the United Kingdom, we also drew from global evidence on vaccine hesitancy. In view of the urgency of the public health need, our approach to intervention development was pragmatic and took advantage of existing data where possible and appropriate. Evaluation of the intervention is underway and will be the focus of future work.

Methods and results

Our development involved four main stages and included the involvement of public and patient partners throughout:

Stage 1: In order to understand and identify common reasons for COVID-19 vaccine hesitancy and acceptance, we carried out (a) an analysis of existing survey data collected within the United Kingdom during the pandemic, (b) a rapid systematic literature review drawing from international literature and (c) an examination of qualitative findings from a series of public engagement workshops regarding views of the public to immune challenges and vaccines.

Stage 2: We synthesised evidence from independent experts. This entailed qualitative interviews with experts from a range of relevant disciplines to identify evidence-based responses to the most common vaccine concerns raised by the public identified in stage 1.

Stage 3: We developed ‘therapeutic dialogues’ to address common vaccine hesitancy concerns. These were developed in a workshop bringing together experts in psychological and digital behaviour change interventions.

Stage 4: The digital intervention was developed.

As this was a linear process, with each stage informing the next, we present the methods and results from each stage consecutively.

**Stage 1.** Understanding and identifying common reasons for hesitancy & acceptance.

**Analysis of existing survey data**

As part of a separate study into the UK population’s mental and physical health over the course of the pandemic, we collected data regarding COVID-19 vaccination intention between 11th–30th November 2020 during the second national lockdown and prior to the rollout of the vaccines (3rd December 2020). During this period, daily case rates peaked at 24,962 (15th November 2020).\(^{14}\) A detailed description of this study and the recruitment processes has been published previously.\(^{13}\) But in relation to vaccine intention, respondents were asked ‘If you were offered a COVID-19 vaccine, would you take it?’ and also asked, through a free text response, to elaborate on their main reason(s) for this intention. This item gave participants space to provide single or multiple responses, all of which were coded and analysed for common themes. One researcher (RJ) conducted a preliminary review of the free text data, allowing the generation of initial themes. To enhance reliability, a second researcher (KA) independently examined the emerging themes, allowing further refinement. The frequency at which these themes appeared was quantified. Where vaccine hesitancy was indicated, themes were categorised within the WHO 3Cs model of vaccine hesitancy, which proposes that three main factors influence the decision to accept vaccines: confidence, complacency, and convenience.\(^{4}\) All coding and categorisation was conducted with high levels of initial agreement (91% for reasons associated with vaccine hesitancy and 85% for reasons associated with the agreement to vaccination). All discrepancies were resolved by discussion.

A total of \(n = 762\) individuals provided data (22% of whom indicated they were hesitant about receiving a COVID-19 vaccination); 93% (\(n = 709\)) of respondents also provided a free-text response indicating their reasons for vaccine acceptance or hesitancy, of which 96% (\(n = 683\)) provided sufficient detail for reasons to be categorised into themes. For those who expressed vaccine hesitancy, the most common concerns were found to map on to the WHO 3C category of ‘confidence’ (e.g. concerns related to long-term complications, side effects and insufficient testing of the vaccines). The second most common concern related to ‘complacency’ (e.g. beliefs of low personal risk of COVID-19, beliefs in the ability to fight off the infection naturally). Concerns related to the ‘convenience’ category were the least common, but where they occurred, they centred on a lack of information about the vaccines and altruism (i.e. other people needing the vaccines more) (see Table 1a). In contrast, in respondents who indicated they would be willing to receive a COVID-19 vaccine, common reasons given related to ‘self-protection’, followed by ‘hope to end the pandemic/wish for normal life’ and a desire to ‘protect the population or unspecified others and control the virus’ (see Table 1b).

**Rapid systematic literature review**

For identifying additional themes/reasons for COVID-19 vaccine hesitancy that may have not been captured in our survey, a rapid systematic literature review was conducted. Four electronic databases (Medline, PsycINFO, Medrxiv, PsyArxiv) were searched to identify peer-reviewed journal articles and pre-prints, which examined reasons for COVID-19 vaccine hesitancy dated between 01/01/2020 and 03/12/2020: using the following search terms: (COVID-19 vaccine hesitancy) OR ((COVID-19) AND (vaccine hesitancy)). Randomised controlled trials (RCTs), mixed methods trials, cohort, and qualitative studies with adult participants were included. One researcher (RJ) conducted abstract and full-text screening to determine eligibility, and a second cross-checked all eligibility decisions (KA). Following title and abstract screening, 49 articles remained for full-text screening, with 10 ultimately deemed suitable for inclusion summarised in Table 2.\(^{15–24}\) The
primary reason for excluding articles at the full-text screening stage were that many studies looked at vaccine intention only, not reasons for vaccine hesitancy (see Fig. 1). Three of the studies were conducted in the United States, and two in the United Kingdom. The remaining five studies were conducted in Nigeria, Mainland China, Hong Kong, France and Malta, respectively. Six studies identified reasons for vaccine hesitancy based on survey questions where a pre-selected list of potential reasons was given. Three studies coded free-text responses to survey questions, and one study analysed participant interviews. Six of the studies collected data from a general population sample, three collected data from health care workers and one did both.

Findings from both the quantitative and qualitative studies included in the review were categorized according to the 3C model. The most common themes identified in this review mirrored those identified in our survey. However, the following additional themes were identified: (1) general vaccine scepticism (i.e. mistrust of pharmaceutical industry); (2) cost of vaccines; (3) concerns relating to vaccine contents; (4) timing of vaccination in relation to the state of the pandemic and (5) concern that the vaccine might result in COVID-19 disease (see Table 2).

Additional insights from public and patient involvement (PPI)

Of the initial survey sample, 9.5% were from ethnic minority groups. To supplement the views of ethnic minorities captured in the survey, we also consulted PPI groups. To supplement the views of ethnic minorities captured in the survey, we also consulted PPI groups. To supplement the views of ethnic minorities captured in the survey, we also consulted PPI groups.

| WHO 3C category | Themes | Count | Examples of free text responses |
|-----------------|--------|-------|--------------------------------|
| Confidence      | Concerns about unknown long-term effects | 39 | It hasn’t been long enough to see if there are any long-term risks’ ‘Uncertainties around long-term effects’ ‘Unknown long term side effects’ |
|                 | Concerns about side effects | 39 | ‘I don’t have full information about its side effects’ ‘Undiscovered side effects/uncertainty of the side effects’ ‘Unknown long-term side effects’ |
|                 | Concerns there is an insufficient testing/evidence base | 37 | ‘Not sure it has been tested thoroughly’ ‘Unclear rigour of the testing/clinical trial results/statistics, etc.’ |
|                 | Concerns the development of the vaccine has been rushed | 27 | ‘It has not been tested at a scale’ ‘Its development and production has been rushed through’ ‘Feels rushed compared to normal vaccine standards’ |
|                 | Concerns about the safety of the vaccine (but not explicitly side effects) | 21 | ‘I don’t think there has been sufficient time to know fully the effects of it’ ‘I’m concerned about its safety’ ‘Would want to be 100% sure it was safe’ ‘Would only take it if I was convinced it was 100% safe’ |
|                 | Unsure about vaccine effectiveness | 14 | ‘I would like the research evidence about its effectiveness rate (in different age groups especially 60+ )’ ‘Not sure about how effective are they, especially as if you get COVID you can get it again. The vaccines antibodies are not as effective as getting the virus itself’ ‘Would prefer a vaccine that stops transmission, not just stop me showing symptoms’ |
|                 | Concerns around vaccine interactions/ effectiveness with existing conditions | 10 | ‘I’m pregnant/breastfeeding so unsure about the effects on my child’ ‘I have auto immune disease’ ‘I have a chronic condition/treatment/operation so unsure about effects of the vaccine will have on me’ |
|                 | Lack of trust in the manufacturer/government/scientists etc. | 9 | ‘It is not in Government or manufacturers’ interests to tell the truth about side effects and adverse reactions’ ‘The poor management of the pandemic by the government reduces my confidence in the safety and efficacy of a vaccination programme’ ‘Don’t trust it/an American vaccine’ |
| Complacency     | Believe they are not at high risk of COVID-19 | 7 | ‘I’m not in a risk category’ ‘I don’t want it at this stage as I’m not at high risk of getting COVID’ ‘I prefer my body to deal with it in its own way’ ‘I believe maintaining strong immune system is best defence’ ‘I am not in a risk category and I limit my vaccinations to things that potentially have very serious consequences for me’ |
|                 | Believe they are in good health/Their body can fight off the virus | 6 | ‘I’ve had COVID already so should be okay for a few months at least’ ‘Would like to know more about antibodies and the likelihood of getting COVID twice’ ‘I’d want to know if I have the antibodies already’ ‘More at-risk people need it first’ ‘It should be delivered to needy first, I’ll have to wait for offer’ ‘I’m fit and healthy that there are more vulnerable people who need it before I do’ |
|                 | Have already had COVID-19 | 3 | ‘I would like to know more about it’ ‘I need to be educated about it first’ ‘I want more information and I need to research about it before accepting it’ ‘I have been told it is very uncomfortable’ |
| Convenience     | Other people need it more | 7 | ‘More at-risk people need it first’ ‘It should be delivered to needy first, I’ll have to wait for offer’ ‘I’m fit and healthy that there are more vulnerable people who need it before I do’ |
|                 | Lack of knowledge about the vaccine | 18 | ‘More at-risk people need it first’ ‘It should be delivered to needy first, I’ll have to wait for offer’ ‘I’m fit and healthy that there are more vulnerable people who need it before I do’ |
|                 | Don’t like injections/vaccine experience | 2 | ‘I would like to know more about it’ ‘I need to be educated about it first’ ‘I want more information and I need to research about it before accepting it’ ‘I have been told it is very uncomfortable’ |
|                 | Inconvenience | 1 | ‘More at-risk people need it first’ ‘It should be delivered to needy first, I’ll have to wait for offer’ ‘I’m fit and healthy that there are more vulnerable people who need it before I do’ |
|                 | Freedom of choice | 1 | ‘If it was a requirement by law, I would not want it, freedom of choice is important’ |
meetings that specifically sought the views of Black, Asian and Minority Ethnic (BAME) individuals. The feedback from all the consultation meetings was reviewed and was found to reveal considerable overlap in the vaccine concerns identified in these meetings, with those identified as part of our survey and literature review. The only additional concerns related to whether vaccines had been tested on people from different ethnic groups and issues of trust in the medical and scientific communities. These issues were, therefore, prioritised for inclusion in our intervention.

Synthesising findings from Stage 1 to identify the most common reasons for vaccine hesitancy

The evidence emerging from the survey, rapid literature review and PPI findings were then triangulated through discussion between the two behavioural scientists (RJ, KA) contributing to this stage of the work. The aim of these discussions was to identify the most common COVID-19 vaccine concerns. This was based in part on the frequency with which concerns were identified in the survey, review, and PPI findings, ensuring that all three domains of the WHO 3C model were represented and that any unique perspectives raised by ethnic minority participants were also captured.

This led to the identification of nine core COVID-19 vaccine concerns. Concerns that were endorsed by fewer than 0.5% of the sample and did not align with concerns identified within the literature and PPI groups were not included within the intervention (i.e. vaccination is "inconvenient"; Table 1a). In keeping with the most frequently cited concerns being related to "confidence", 5/9 concerns related to "confidence" (i.e. generalisability of evidence on vaccine safety and effectiveness to diverse populations; side-effects; rapid nature of vaccine development; clinical effectiveness and vaccine scepticism). Two out of nine concerns related to "complacency" (i.e. low perceived risk of COVID-19 and belief in the ability to fight off the infection naturally). A further two concerns related to "convenience" (i.e. perceived lack of knowledge about COVID-19 vaccine and altruistic beliefs regarding others having a greater need). A tenth concern was subsequently added when the UK government decided to alter the dosing schedule from 3/4 weeks to up to 12 weeks between the two doses recommended for the Astra Zeneca and Pfizer vaccines. In keeping with the WHO 3C model, this latter issue is also related to the issue of 'confidence'. Each theme/concern was given equal weighting within the subsequent development process.

Stage 2. Synthesising the evidence-based views of independent experts.

Following the identification of 10 core vaccine concerns (Table 3) we sought to gather evidence-based responses to these concerns. This was achieved through semi-structured interviews with six academic and clinical experts from the fields of public health, general medicine, respiratory medicine and immunology with particular expertise in COVID-19 and/or COVID-19 vaccines. Each expert was presented with the list of 10 concerns and asked to provide an evidence-based response to each concern based on their knowledge of the scientific literature at that time. Interviews with experts were subjected to rapid thematic and content analysis after each interview, and interviews continued until saturation in responses was achieved (i.e. no new responses emerged).25

The expert responses demonstrated significant thematic overlap and consistency. Table 3 summarises the areas of evidence cited by experts in response to each concern.

Stage 3. Developing therapeutic dialogues to address common vaccine hesitancy concerns.

Our approach to developing the intervention was predicated on two main observations of the existing evidence. First that psycho-education alone (i.e. provision of information gathered in Stage 2) is unlikely to be an effective way to address COVID-19 vaccine concerns. Second that a central pillar of our approach should be to acknowledge and engage with individuals’ concerns in a supportive context. To achieve this, we sought to develop ‘therapeutic
### Table 2
Summary of studies included in rapid literature review.

| Author                  | Region        | Study design                          | Population                          | Sample size | Themes or responses with frequencies\(^a\) |
|-------------------------|---------------|---------------------------------------|-------------------------------------|-------------|------------------------------------------|
| Adesini et al., 2020\(^5\) | Nigeria       | Survey question with listed answers    | General public                      | N = 517 (n = 132 provided reasons for vaccine hesitancy) | Unreliability of the clinical trials (37.1%); immune system is sufficient (27.3%); the vaccine is not safe (16.7%); COVID-19 vaccine is likely to be expensive (6.8%); other reasons (12.1%) Specifc concerns about the vaccine (82.6%, side effects/safety, efficacy, newness, including not wanting to be the first to get the vaccine, rigour of testing, vaccine contents). Need additional information (24.7%, compatibility with personal health conditions e.g. allergies, comorbid conditions, recommendation from doctor or official, timing regarding state of pandemic, personal immunity, need more information unspecified). Anti-vaccine attitudes, beliefs, and emotions (76.6%, don't need the vaccine e.g. not at risk, religious beliefs, don't believe the vaccine will work informed by reference to other bad vaccine experiences/flu shots not working/ vaccine won't work against mutation organism, general statements about not getting vaccines, not comfortable with vaccines, fear about vaccines, misconceptions/incorrect information about vaccines). Lack of trust in vaccines, government and Centers for Disease Control and Prevention (CDC), pharmaceutical companies, vaccine development or testing process, reference to specific conspiracy theories, distrust unspecified (45.2%). Other (9.8%, altruism i.e. wanting higher risk individuals to get first, cost, dislike of needles). Concerns about vaccine safety: newness of vaccine, effectiveness of the vaccine. Cost of the vaccine. |
| Fisher et al., 2020\(^6\)    | US            | Open ended question                    | General public                      | N = 1003 (n = 303 provided reasons for vaccine hesitancy) | 'I'm confident there will be other effective treatments soon' (13%) 'I don't yet know enough about the vaccine to make a decision' (14%) 'I want to gain natural immunity to the virus that causes covid-19' (2%) Development of the vaccine may be rushed/the vaccine may not be thoroughly tested prior to approval (15%) 'I believe vaccines may give you the disease they are designed to protect against' (1%) 'I don't know' (13%) The majority of the COVID-19 vaccine-related concerns were long-term side effects and insufficient knowledge about the vaccine. Other concerns included: short-term side effects (e.g. fever), vaccine effectiveness and general anti-vaccine attitudes. General opposition to vaccines; concerns that the vaccine would not be effective; not personally required (don't need to get vaccinated); lack of trust in government and pharmaceutical industries. |
| Fu et al., 2020\(^7\)          | Mainland China | Survey question with listed answers    | Health care workers and general population | N = 541 (n = 445 provided responses in relation to vaccine hesitancy) | 'I don't yet know enough about the vaccine to make a decision' (14%) 'I want to gain natural immunity to the virus that causes covid-19' (2%) Development of the vaccine may be rushed/the vaccine may not be thoroughly tested prior to approval (15%) 'I believe vaccines may give you the disease they are designed to protect against' (1%) 'I don't know' (13%) The majority of the COVID-19 vaccine-related concerns were long-term side effects and insufficient knowledge about the vaccine. Other concerns included: short-term side effects (e.g. fever), vaccine effectiveness and general anti-vaccine attitudes. General opposition to vaccines; concerns that the vaccine would not be effective; not personally required (don't need to get vaccinated); lack of trust in government and pharmaceutical industries. |
| Gadoth et al., 2020\(^8\)      | US            | Free-text question                     | Health care workers                  | N = 1069 (n = 609 provided responses in relation to vaccine hesitancy) | 'I don't yet know enough about the vaccine to make a decision' (14%) 'I want to gain natural immunity to the virus that causes covid-19' (2%) Development of the vaccine may be rushed/the vaccine may not be thoroughly tested prior to approval (15%) 'I believe vaccines may give you the disease they are designed to protect against' (1%) 'I don't know' (13%) The majority of the COVID-19 vaccine-related concerns were long-term side effects and insufficient knowledge about the vaccine. Other concerns included: short-term side effects (e.g. fever), vaccine effectiveness and general anti-vaccine attitudes. General opposition to vaccines; concerns that the vaccine would not be effective; not personally required (don't need to get vaccinated); lack of trust in government and pharmaceutical industries. |
| Grech et al., 2020\(^9\)       | Malta          | Survey question with listed answers    | Family physicians and trainees       | N = 350 (n = 123 provided responses in relation to vaccine hesitancy) | 'I don't yet know enough about the vaccine to make a decision' (14%) 'I want to gain natural immunity to the virus that causes covid-19' (2%) Development of the vaccine may be rushed/the vaccine may not be thoroughly tested prior to approval (15%) 'I believe vaccines may give you the disease they are designed to protect against' (1%) 'I don't know' (13%) The majority of the COVID-19 vaccine-related concerns were long-term side effects and insufficient knowledge about the vaccine. Other concerns included: short-term side effects (e.g. fever), vaccine effectiveness and general anti-vaccine attitudes. General opposition to vaccines; concerns that the vaccine would not be effective; not personally required (don't need to get vaccinated); lack of trust in government and pharmaceutical industries. |
| Hacquin et al., 2020\(^10\)    | France         | Interviews                             | General public                      | N = 5028 (n = 1004 provided responses in relation to vaccine hesitancy) | 'I don't yet know enough about the vaccine to make a decision' (14%) 'I want to gain natural immunity to the virus that causes covid-19' (2%) Development of the vaccine may be rushed/the vaccine may not be thoroughly tested prior to approval (15%) 'I believe vaccines may give you the disease they are designed to protect against' (1%) 'I don't know' (13%) The majority of the COVID-19 vaccine-related concerns were long-term side effects and insufficient knowledge about the vaccine. Other concerns included: short-term side effects (e.g. fever), vaccine effectiveness and general anti-vaccine attitudes. General opposition to vaccines; concerns that the vaccine would not be effective; not personally required (don't need to get vaccinated); lack of trust in government and pharmaceutical industries. |
| Kwok et al., 2020\(^11\)       | Hong Kong      | Survey question with listed answers from a scale | Nurses                              | N = 1205 (n = 1205 provided responses in relation to vaccine hesitancy) | Confidence in safety; effectiveness; and trust in other authorities. Complacency regarding whether the disease is common; that the immune system is sufficient to fight off the disease and the disease is not severe. Constraints to getting vaccinated such as everyday stress; inconvenience; visiting the doctors; discomfort. Calculations involving weighing up benefits and risks; needing to closely consider whether it is personally useful; needing to understand more about vaccines and vaccination. |
**Table 2 (continued)**

| Author                | Region | Study design                          | Population          | Sample size                        | Themes or responses with frequencies |
|-----------------------|--------|---------------------------------------|---------------------|------------------------------------|--------------------------------------|
| Pogue et al., 2020    | US     | Survey question with listed answers   | General public      | N = 316 (33.5% provided responses in relation to vaccine hesitancy) | Concerns about vaccine safety (45.5%); lack of trust in the source that encouraged them to receive the vaccine (13.5%); other e.g. need more testing on the vaccines |
| Sherman et al., 2020  | UK     | Survey question with listed answers from a scale | General public      | N = 1500 (n = 1448 provided responses in relation to vaccine hesitancy) | Concerns about safety and side effects of the vaccine; newness of the vaccine; needing sufficient information to make an informed decision; afraid of needles; not at risk of serious illness from COVID; trust in manufacturers/government/health care professionals; |
| Williams et al., 2020 | UK     | Free text question                     | General public      | N = 527 (n = 158 provided reasons for vaccine hesitancy) | Concerns about vaccine safety (100%) centred on the newness of the vaccine and its safety (e.g. long-term effect, side effects) and effectiveness. |

*Themes or responses were based on participants who provided information on vaccine hesitancy.*

**dialogues’** based on the communication principles of motivational interviewing (MI), including:

- **Expressing empathy:** cultivating an empathic space with which to explore hesitancy
- **Developing discrepancy:** identifying areas in which a person’s actions are misaligned with their personal values and goals
- **Embracing resistance:** working collaboratively with an individual to foster change and recognising when that resistance and motivation are intricately tied

![Fig. 1. PRISMA summary of search procedure.](image-url)
Supporting self-efficacy: enhancing confidence that an individual can embark on change.26

MI was considered an appropriate approach because individuals who are vaccine-hesitant are, by definition, not ready to, or ambivalent about, changing their cognitions and behaviour and MI is known to be effective in such contexts.27,28 Thus, for each of the most common vaccine concerns identified in Stage 1 we developed a therapeutic dialogue, which would both impart information relevant to the individual concern, but do so using the communication principles of MI with a view to facilitating cognitive and, in turn, behaviour change, i.e. reduce hesitancy and improve vaccine uptake.

| Concern | Key responses |
|---------|---------------|
| **I don't know if the vaccines have been tested on people like me:** | The vaccines have been trialled in 10s of 1000s of people across many countries and ethnicities. No discernible difference in response to the vaccine across ethnic groups or age groups. |
| • By age, ethnicity, and comorbid health condition | Researchers included individuals with common chronic health conditions in the trials to ensure any risks to this population were identified. Pregnant and breastfeeding women were not included in the trials. |
| **I don't think we know enough about the side-effects of the vaccines** | All COVID-19 vaccines have undergone very robust testing, including pauses to trials to explore whether adverse events or allergic reactions were as a result of the vaccine itself. These vaccines follow the same trial protocols for reporting adverse events to the medical advisory boards that all other vaccines must follow. All vaccines come with the chance of immediate side effects, such as a sore arm, fever etc. This shows the immune system has responded to the vaccine. Short-term side effects are similar to all other vaccines. |
| **I think the whole process has been rushed** | The vaccines have followed the same development criteria that all vaccines must undergo. Many other vaccines are developed in a similar time frame, such as the flu vaccine. The difference in timeframes has resulted in the concerted channeling of funds into the development of these vaccines, with governments, manufacturers, and scientific bodies providing substantial and rapid funding, expediting the researchers’ ability to test the vaccines. Some vaccines, such as the Oxford AstraZeneca vaccine, were developed quickly because the researchers utilised an existing vaccine formula and inserted in an inert form of the COVID-19 virus. New technology also allowed us to identify the genetic make-up of the virus much more quickly. Evaluation of the safety of the vaccine by independent regulators (MRHA) was expedited as the regulators prioritised reviewing the trial data. |
| **I don't know if they will work** | The data suggests short-term protection of at least 3 months. Pfizer vaccines is highly effective in the short term — approximately 95%. Oxford-AstraZeneca rates varied, but were approximately 70% effective. However, long-term data has yet to be reported. We don’t know yet if the vaccines prevent transmission. |
| **I don't think I am at risk of getting COVID-19** | While many people experience mild symptoms, COVID-19 is unpredictable; we are not able to predict who will be adversely affected. Although COVID-19 affects older people most severely, a significant proportion of those hospitalised are under the age of 60. We know that you can contract COVID-19 more than once and are unsure how long any immunity to the virus lasts after exposure. The vaccines offer protection against the virus and prevent the risk of experiencing a severe form of the disease. Receiving a vaccine could prevent you from requiring hospitalisation. Vaccination reduces the volume of the population who can contract and spread the virus, reducing the disease burden in the community. |
| **I think my body can fight the virus on its own** | Younger individuals are less likely to experience severe COVID-19, however there is still the risk of this happening. It is also possible to get re-infected with the virus, although evidence suggests the reinfecion results in less severe illness. The immune system can exhibit extreme reactions to the COVID-19 virus, but it is very unlikely to react in such a way to the vaccines. Reducing your risk of contracting and therefore spreading COVID-19 helps to protect others. Reducing your risk of contracting COVID-19 also means you are much less likely to need to self-isolate. The vaccines all significantly reduce the risk of contracting severe COVID-19. Effectiveness has been shown in individuals of all ages, ethnic backgrounds, and with other health conditions. No serious side effects have been reported; participants in the early trials have now been monitored for almost 12 months. The MHRA have been monitoring the vaccines’ safety extremely carefully, as they do with all other vaccines. The Joint Committee for Vaccines and Immunisations (JCVI) has identified a priority list for vaccine disseminations. If someone is offered a vaccine, it means they have been identified as being in a priority group. Receiving a vaccine does not detract from someone else receiving a vaccine. |
| **Other people need it more than me** | The Joint Committee for Vaccines and Immunisations (JCVI) has identified a priority list for vaccine disseminations. Vaccines save millions of lives every year and there is no evidence for adverse effects of the COVID-19 vaccines. This decision was taken because it allows twice as many people to get some protection against the virus, offering the greatest opportunity to save lives. The first vaccination offers short-term protection, while the second booster dose provides long-term protection. Delaying the second dose from 3 to 12 weeks also gives the immune system longer to develop immunity. In the Oxford-AstraZeneca vaccine trials, a longer gap between doses offered better protection. |
| **I just don't know enough about it:** | Safety and effectiveness concerns Effectiveness has been shown in individuals of all ages, ethnic backgrounds, and with other health conditions. No serious side effects have been reported; participants in the early trials have now been monitored for almost 12 months. The MHRA have been monitoring the vaccines’ safety extremely carefully, as they do with all other vaccines. The Joint Committee for Vaccines and Immunisations (JCVI) has identified a priority list for vaccine disseminations. If someone is offered a vaccine, it means they have been identified as being in a priority group. Receiving a vaccine does not detract from someone else receiving a vaccine. |
| **I don't believe in vaccines:** | Safety and effectiveness concerns Vaccines save millions of lives every year and there is no evidence for adverse effects of the COVID-19 vaccines. This decision was taken because it allows twice as many people to get some protection against the virus, offering the greatest opportunity to save lives. The first vaccination offers short-term protection, while the second booster dose provides long-term protection. Delaying the second dose from 3 to 12 weeks also gives the immune system longer to develop immunity. In the Oxford-AstraZeneca vaccine trials, a longer gap between doses offered better protection. |

Table 3
Expert responses to 10 most common reasons for vaccine hesitancy.
An online format was chosen to deliver the therapeutic dialogue to maximise audience reach and engagement, supported by substantial evidence based on the use of this modality to promote vaccine uptake.29,30

Development of the therapeutic dialogues occurred through several expert workshops with behavioural scientists with expertise in MI, therapeutic interventions, digital interventions, behaviour change and COVID-19. First, key themes identified in the expert interviews (Stage 2) were discussed and translated into conversational language. The investigators chose a conversational approach to align with the online delivery format and ensure inclusivity for all reading/English levels (see stage 4 below). Second, the dialogues were reviewed to identify points at which MI techniques could be integrated throughout. This process drew on contributors’ experience in behaviour change research and adopted the approach proposed by Rollnick and colleagues.26 This included expressing empathy through the use of accepting and non-judgemental language. By developing discrepancy by simultaneously providing information related to the concern and presenting a rationale for vaccine uptake. The latter were derived from survey respondents willing to accept a COVID-19 vaccine (see Table 1b) and sought to develop a discrepancy between the individual’s cause for concern and their wider personal values and goals. By embracing resistance by acknowledging that their concerns are shared by others and are legitimate and supporting self-efficacy by reinforcing the individual’s personal agency in making their decision to accept a vaccine or not. See Table 4 for illustrative examples of how MI principles were embedded within the therapeutic dialogues.

Finally, we hosted a PPI workshop to discuss the resulting dialogues. Participants were members of the general public recruited through the University Hospital Southampton NHS Foundation Trust PPI team. The workshop was advertised as an opportunity to provide feedback about an online tool designed to answer the public’s questions about the COVID-19 vaccines. Four individuals responded to the advertisement and attended the workshop. The group, while small, included two adults less than 30 years (two greater than 50 years); three women and one man and all reported interest in vaccine hesitancy and had some experiences of it among friends and family. All participants were paid for their time. The feedback obtained through this workshop fostered changes to their readability, along with an expansion of the information conveyed and greater consideration of specific groups within the population (i.e., those who have allergies or specific religious and cultural needs). No additional vaccine concerns were identified by the group.

Stage 4. The digital intervention.

The script from each of the 10 therapeutic dialogues provided the architecture for our digital, web-based vaccine hesitancy intervention. Given high rates of internet usage throughout the United Kingdom (92% of adults)31 and other similar developed countries, it was felt that the use of a digital platform would maximise reach and accessibility. The research team worked with a digital development company to design and build a conversational interface through which individuals identify the issue that most closely underpins their reason for being hesitant (from the issues stated above, e.g., concerns about side effects). This identification triggers an MI driven therapeutic dialogue relevant to the selected concern, with opportunities for the individual to further explore the content as they progress through the dialogue, as well as to access responses to more than just their initial concern.

Once developed, the digital intervention was piloted with 18 members of the public (nine male/nine female) who had no previous experience with the dialogues. Participant feedback on the dialogue content, user interface, accessibility, and general presentation led to a final iteration of the intervention, which can be viewed here: www.covidvaxfacts.info. For illustrative screenshots, see Supplementary Figs. 1 and 2.

Discussion

The development of safe and effective vaccines against SARS-CoV-2, while necessary, will not be sufficient to contain COVID-19 unless we also achieve high vaccine uptake. We have described here the rapid development of an evidence-based digital intervention, which draws on the communication principles of MI and is in keeping with many of the recommendations made in a recent review of approaches to increasing vaccine uptake, e.g., focus on the concerns of the population.25 Our aim is to provide the end-user with an intervention that is individualised to their specific concerns, acknowledges the legitimacy of these concerns, provides up to date information related to these concerns while also providing an accepting non-judgemental context in which they can explore their reasons for hesitancy. The text-based content and digital format mean it can be readily scaled-up for wider dissemination and rapidly modified for implementation in different languages and to respond to changing information.

Table 4
Exemplars of how MI principles were included within the therapeutic dialogues.

| Concern                                                                 | Motivational interviewing concept | Concept example utilised in the dialogue |
|------------------------------------------------------------------------|-----------------------------------|----------------------------------------|
| ‘I don’t know if the vaccines have been tested on people like me’      | Expressing empathy:               | These are brand new vaccines and it is completely understandable that you would ask about their safety |
|                                                                         | • Including reflective listening  |                                           |
|                                                                         | of follow up questions to engage user |                                           |
| ‘I don’t believe I am at risk of getting COVID-19’                     | Developing discrepancy:           | So when you choose to have a vaccination you are also choosing to protect others, to take the pressure off the NHS, and helping us all get back to normal. |
|                                                                         | • Identifying potential areas of conflict between vaccine hesitancy and personal values |                                           |
| ‘I don’t think we know enough about the side-effects of the vaccines’  | Embracing resistance:             | And you are not alone in wondering about this. Scientists, doctors, the independent regulator who decide on which medicines can be offered to the public (the Medicines and Health care Products Regulatory Agency) all want to know how well the vaccines work. |
|                                                                         | • Recognising resistance and helping to move forward collaboratively |                                           |
| ‘I don’t know if the vaccines have been tested on people like me’      | Supporting self-efficacy          | We hope we have been able to help with your concerns about the safety of the vaccines. To sum up, they have all been monitored very closely to find side effects. But if you did experience a side effect it is most likely to be very minor and much less severe than catching COVID-19. |
|                                                                         | • Enhancing confidence to make an informed decision about whether to receive a vaccine |                                           |
Although this intervention, like much else to do with COVID-19, has been developed at a pace, we think the process highlights some potential issues regarding intervention development worthy of discussion. First, the development of our digital, behavioural intervention followed a fairly conventional path as outlined in the Medical Research Council’s (MRC) best practice guidance. This involved evaluating the evidence base and theory, as well as incorporating the views of target users (i.e. members of the general public). This was possible partly because we had timely access to PPI findings available through the University Hospital Southampton NHS Foundation Trust regarding the acceptability of vaccines, allowing rapid comparison of the PPI findings with the concerns identified through our existing survey data and literature review.

A critical step in digital intervention development is the optimisation of intervention content since digital intervention content cannot be adjusted ‘in the moment’, like in a practitioner delivered intervention. We were able to conduct optimisation work with PPI, albeit with a smaller sample (N = 4) than might usually be employed in digital intervention development. Computer science methodology states that during an intervention, optimisation around 80% of views can be captured with five target users, and we were close to this threshold. However, best practice guidance from digital health psychology suggests including larger, diverse samples is important to quickly view people from different backgrounds are considered. Despite having a smaller sample, our optimisation with PPI did help us to improve the persuasiveness and accessibility of the key messages within the intervention. It is possible that we may have found other important ways of optimising our content by including a larger, more diverse group of PPI at this stage. However, it is important to note that this intervention is quite simple; it targets only one behaviour, draws on a very well-established behavioural technique, which guided content design (MI), and it addressed barriers that were thoroughly identified using existing evidence in the intervention planning stage. Therefore, in this particular context, it is possible that sufficient optimisation was achieved with a smaller sample. Following launching the intervention, we were able to remain responsive to changes in the vaccine guidance by seeking expert advice in relation to the risk of blood clots, protection against emergent variants, pregnancy, and vaccination during Ramadan. Expert responses on these topics were compiled into a breaking news section and updated within the dialogues in line with government recommendations. Delivering the intervention digitally provides a rapid means of evaluating and evolving the intervention as reasons for hesitancy change, allowing real-time collection of both analytics and usage data alongside data that might answer specific research questions.

The MRC highlights the importance of making use of existing data and evidence wherever possible. In this work, we were able to benefit from data collected as part of another study37 where we were able to identify specific concerns related to vaccine hesitancy. We also drew on evidence kindly shared with us by others. This allowed acceleration of the intervention development and improved the economic efficiency of research.

In view of the urgency of the public health issue, we conducted a rapid review. Given the rapid evolution of the scientific landscape, we acknowledge that new work may have since emerged. However, to the author’s knowledge, recent work provides evidence on the persistence of the primary concerns underpinning this intervention within the general public. Indeed, COVID-19 has most likely led to an unprecedented number of rapid reviews, as the scientific community have clamoured to understand the available evidence as quickly as possible. Although it is clear that rapid reviews take many forms (e.g. limited by language, dates, databases etc.), they do vary in the quality of their reporting and the methodological shortcuts they take. The implications of these inconsistencies for the quality and validity of these reviews is, however, unclear as there is thus far limited evidence comparing the results of different review approaches. The provision of such evidence in future research would undoubtedly inform the contexts in which it is appropriate to conduct rapid reviews and the methods that should be employed. Such guidance now exists for scoping reviews,38 and would appear to be in development for rapid reviews by the Equator network.

While we have attempted to create an intervention that is scalable, limitations to our work are noted. Although the development of the intervention was predicated on findings from the international literature and incorporated feedback from an ethnically diverse PPI group, the survey data used in Stage 1 was collected from a predominantly white sample (90.3%) within the East Midlands. Given elevated rates of vaccine hesitancy amongst ethnic minority groups, a targeted approach to the development and rollout of future interventions is warranted. Additionally, participants were asked to report their own concerns about receiving a vaccine; however, these concerns may have changed over the course of vaccine rollout and be influenced by an individual’s social networks and the media. Exploring temporal changes to vaccine hesitancy and the impact of external factors on intrinsic concerns is a worthwhile avenue for future research. Finally, while the utility of delivering an intervention digitally is relevant for countries with high internet usage, the mechanism for delivery in less developed countries requires careful consideration. However, it is hoped that this paper provides a framework for future iterations of rapid behavioural interventions, which can be adapted to meet the unique needs of the population and behaviour of choice.

Conclusion

In summary, for COVID-19 vaccines to achieve their full public health potential, the public need to be willing to be vaccinated. Recent data suggest this cannot be assumed. We have reported here on the development of a scalable digital intervention that seeks to address the concerns of individuals who are vaccine-hesitant with a view to enhancing their confidence in COVID-19 vaccines, and in turn, their uptake. The effects of the intervention on these outcomes will be the subject of future work.

Author statements

Acknowledgements

We would like to thank all experts for their contributions to the expert interviews. This work was supported by the School of Primary Care Research [Grant Number 434] with in-kind support from the National Institute for Health Research ARC Wessex.

Ethical approval

None sought.

Funding

This work and the salary of KA were supported by the School of Primary Care Research [Grant Number 434]. JRM and HK receive salary support from a Medical Research Council Clinician Scientist Fellowship [grant number MR/P008348/1].

Competing interests

The authors declare that they have no known competing financial interests or personal relationships that could have
appeared to influence the work reported in this paper. This report is independent research supported by the National Institute for Health Research (ARC) Wessex. The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research, Medical Research Council, or the Department of Health and Social Care.

Authorship contribution statement

HK, KV, KB, KB, TC: conceptualisation, data analysis, writing original draft, reviewing and editing. RJ, KA: Conducted rapid literature review, writing of original draft, reviewing and editing. JRM, LD: conceptualisation, expert contributions through qualitative interviews, reviewing and editing. TA, JB, CB, RB, TMK: reviewing and editing.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.puhe.2021.10.006.

References

1. https://www.worldometers.info/coronavirus/countries-where-coronavirus-has-spread/; [Accessed 9 February 2021].
2. Pan K-Y, Kok AAL, Eekelenboom M, Horstfall M, Jörg F, Luteijn RA, et al. The mental health impact of the COVID-19 pandemic on people with and without depressive anxiety, or obsessive-compulsive disorders: a longitudinal study of three Dutch case-control cohorts. Lancet Psychiatry 2021;8:1211–9.
3. Robertson E, Reeve KS, Niedzwiedz CL, Moore J, Blake M, Green M, et al. Preventing COVID-19 vaccine hesitancy in the UK household longitudinal study. medRxiv 2021:2020.12.27.20248899.
4. The Sage Working Group. 2014. https://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf.
5. Paul E, Steptoe A, Fancourt D. Anti-vaccine attitudes and risk factors for not agreeing to vaccination against COVID-19 amongst 32,361 UK adults: implications for public health communications. medRxiv 2020:2020.10.21.20126128.
6. Loomba S, de Figueiredo A, Platek SJ, de Graaf K, Larson HJ. Measuring the impact of exposure to COVID-19 vaccine misinformation on vaccine intent in the UK and US. medRxiv 2020:2020.10.22.20177513.
7. Anderson RM, Veggari C, Truscott J, Colyer BS. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet 2020;396:1614–6.
8. Abdullahi LH, Kagina BM, Ndze VN, Hussey GD, Wiysonge CS. Improving vaccination uptake among adolescents. Cochrane Database Syst Rev 2020:10.D011895.
9. Fricascia B, Oradini-Alacreu A, Balzarini F, Signorelli C, Lopalo PI, Odono A. Effectiveness of email-based reminders to increase vaccine uptake: a systematic review. Vaccine 2020;38:338–43.
10. Bisset KA, Paterson P. Strategies for increasing uptake of vaccination in pregnancy in high-income countries: a systematic review. Vaccine 2018;36:2751–9.
11. Dubé E, Gagnon D, MacDonald NE. Strategies intended to address vaccine hesitancy: review of published reviews. Vaccine 2015;33:4191–203.
12. Bach AT, Kang AY, Lewis J, Xaviere S, Portillo I, Goad JA. Addressing common barriers in adult immunizations: a review of interventions. Expert Rev Vaccines 2019;18:1167–85.
13. Jia R, Aylng K, Chalder T, Massey A, Broadbent E, Coupland C, et al. Mental health in the UK during the COVID-19 pandemic: cross-sectional analyses from a community cohort study. BMJ Open 2020;10.e046020.
14. Gov.UK. Cases in United Kingdom. https://coronavirus.data.gov.uk/details/cases/. [Accessed 23 July 2021].
15. Adebisi YA, Alaran AJ, Bolarinwa OA, Akande-Sholabi W, Lucero-Prisno DE. When it is available, will we take it? Public perception of hypothetical COVID-19 vaccine in Nigeria. medRxiv 2020:2020.09.24.200436.
16. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes toward a potential SARS-CoV-2 vaccine: a survey of U.S. Adults. Ann Intern Med 2020;173:964–73.
17. Fu C, Wei Z, Pei S, Li S, Sun X, Liu P. Acceptance and preference for COVID-19 vaccination in health-care workers (HCWs). medRxiv 2020:2020.04.09.20060103.
18. Gadoth A, Halfbrook M, Martin-Blais R, Gray A, Tohni NH, Ferbas KG, et al. Assessment of COVID-19 vaccine acceptance among healthcare workers in Los Angeles. medRxiv 2020:2020.11.18.20234468.
19. Grech V, Bonnici J, Zammit D. Vaccine hesitancy in Maltese family physicians and their trainees vis-à-vis influenza and novel COVID-19 vaccination. Early Hum Dev 2020;105259.
20. Haquin M, Altay S, de Araujo E, Chevalier C, Mercier H. Sharp rise in vaccine hesitancy in a large and representative sample of the French population: reasons for vaccine hesitancy. PsyArXiv 2020.
21. Kwok KG, Li KK, Wei VL, Tang A, Wong SYS, Lee SS. Are we ready when COVID-19 vaccine is available? Study on nurses’ vaccine hesitancy in Hong Kong. medRxiv 2020:2020.07.17.20156026.
22. Pogue K, Jensen J, Stancil CK, Ferguson DG, Hughes SJ, Mello EJ, et al. Influences on attitudes regarding potential COVID-19 vaccination in the United States. Vaccines (Basel) 2020:8.
23. Sherman SM, Smith LE, Sim J, Amlôt R, Cutts M, Dasch H, et al. COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVACCs), a nationally representative cross-sectional survey. Hum Vaccines Immunother 2020:1–10.
24. Williams L, Gallant AJ, Rasmussen S, Brown Nicholls LA, Cogan N, Deakin K, et al. Towards intervention development to increase the uptake of COVID-19 vaccination among those at high risk: outlining evidence-based and theoretically informed future intervention content. Br J Health Psychol 2020:25:1039–54.
25. Gale RC, Wu J, Erhardt T, et al. Comparison of rapid vs in-depth qualitative analytic methods from a process evaluation of academic detailing in the Veterans Health Administration. Implement Sci 2019:14:11. https://doi.org/10.1186/s13012-019-0853-y.
26. Rollnick S, Miller WR, Butler C. Motivational interviewing in health care: Helping patients change behavior. New York: The Guilford Press; 2008.
27. Mbaahgabwe L, Ye C, Thabane L. Motivational interviewing for improving outcomes in youth living with HIV. Cochrane Database Syst Rev 2012 Sep;9. CD009748.
28. Gagneur A. Motivational interviewing: a powerful tool to address vaccine hesitancy. Can Comm Dis Rep 2020;46:93–7.
29. Pot M, Paulussen TG, Ruitter RA, Mollema L, Hofstra M, Van Keulen HM. Dose-response relationship of a web-based tailored intervention promoting human papillomavirus vaccination: process evaluation of a randomized controlled trial. J Med Internet Res 2020 Jul 17;22(7):e14822.
30. O’Leary ST, Narwanyj KJ, Wagner NM, Kraus CR, Omer SB, Glanz JM. Efficacy of a web-based intervention to increase uptake of maternal vaccines: an RCT. Am J Prev Med 2019 Oct;57(4):e125–35. Epub Aug 29 2017.
31. Office for National Statistics. Internet users, UK. 2020. https://www.ons.gov.uk/businessindustryandtrade/standardinternetindustry/bulletins/internettusers/2020. [Accessed 27 September 2021].
32. Lawes-Wickwar S, Ghio D, Tang MY, Keyworth C, Stanescu S, Westbrook J, et al. A rapid systematic review of public responses to health messages encouraging vaccination against infectious diseases in a pandemic or epidemic. Vaccines (Basel) 2021:9.
33. Yardley L, Morrison I, Bradbury K, Muller I. The person-based approach to intervention development: application to digital health-related behavior change interventions. J Med Internet Res 2015;17:e30.
34. Nielsen J. Estimating the number of subjects needed for a thinking aloud trial. Int J Hum Comput Stud 1994;41:385–97.
35. Freeman D, Loe BS, Chadwick A, Vaccari C, Waite F, Rosebrock L, et al. COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. Psychol Med 2020 Dec 11:1–15. https://doi.org/10.1017/S0033291720001975.
36. Tricco AC, Antony J, Zarin W, Strifler L, Ghassani M, Ivory J, et al. A scoping review of rapid review methods. BMC Med 2015;13:224.
37. Tricco AC, Liddle E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018;169:467–73.
38. https://www.equator-network.org/library/reporting-guidelines-under-development/reporting-guidelines-under-development-for-systematic-reviews/. [Accessed 5 March 2021].